三孚新科(688359) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥114,411,127.02, a decrease of 14.45% compared to the same period last year[3] - The total profit for the period was a loss of ¥15,142,374.60, with a year-to-date total profit loss of ¥47,341,754.33[3] - The net profit attributable to shareholders was a loss of ¥6,736,531.17 for the quarter, and a loss of ¥29,047,052.16 year-to-date[3] - Total operating revenue for the first three quarters of 2025 was CNY 341.71 million, a decrease of 20.5% compared to CNY 429.93 million in the same period of 2024[16] - Net profit for the first three quarters of 2025 was a loss of CNY 30.96 million, compared to a loss of CNY 6.66 million in 2024, indicating a significant decline in profitability[17] - The basic and diluted earnings per share for the first three quarters of 2025 were both CNY -0.30, compared to CNY -0.18 in 2024, indicating a worsening financial position[17] Research and Development - Research and development expenses totaled ¥17,592,145.32, accounting for 15.38% of operating revenue, an increase of 2.99% year-on-year[4] - Research and development expenses for the first three quarters of 2025 were CNY 50.50 million, slightly down from CNY 54.26 million in 2024[16] - Research and development expenses for the first three quarters of 2025 were CNY 18,069,614.15, down from CNY 21,470,125.52 in the same period of 2024, showing a decrease of approximately 15.5%[24] Assets and Liabilities - Total assets increased to ¥1,363,897,303.81, reflecting a growth of 7.28% from the end of the previous year[4] - The company's current assets reached RMB 729,927,983.78, up from RMB 654,250,875.85, indicating an increase of about 11.5%[12] - Total liabilities decreased to RMB 602,517,779.12 from RMB 625,634,015.89, reflecting a reduction of about 3.7%[14] - The company's total liabilities decreased to CNY 322,419,899.39 as of September 30, 2025, down from CNY 440,316,729.98 at the end of 2024, reflecting a reduction of approximately 26.7%[22] Cash Flow - The company reported a net cash flow from operating activities of ¥22,815,984.81 year-to-date[3] - Operating cash flow for the first three quarters of 2025 was CNY 22.82 million, a recovery from a negative cash flow of CNY 48.01 million in 2024[19] - In the first three quarters of 2025, the net cash flow from operating activities was ¥8,864,001.60, a significant improvement compared to a net outflow of ¥48,320,645.79 in the same period of 2024[26] - The net cash flow from financing activities was negative at -¥20,432,043.72, contrasting with a positive net flow of ¥110,772,986.41 in the previous year[28] Equity - Shareholders' equity attributable to the company increased by 22.29% to ¥621,824,254.43 compared to the end of the previous year[4] - The company's equity attributable to shareholders rose to RMB 621,824,254.43 from RMB 508,469,683.28, an increase of approximately 22.2%[14] - The total owner's equity rose to CNY 676,227,556.02 as of September 30, 2025, up from CNY 499,498,385.66 at the end of 2024, representing an increase of approximately 35.5%[23] Investment Activities - The company recognized non-recurring gains of ¥1,475,866.97 for the quarter, with a total of ¥3,563,670.54 year-to-date[7] - The company reported a significant increase in investment income to CNY 65,829,302.69 in the first three quarters of 2025, compared to CNY 18,586,109.42 in the same period of 2024, reflecting an increase of approximately 253.5%[24] - The company received ¥127,042,455.46 from investment contributions, a notable increase from ¥737,345.00 in the previous year[26] Other Information - The company has not reported any significant new product developments or market expansions in the current content[15] - There are no updates on mergers or acquisitions mentioned in the provided content[15] - The company did not apply new accounting standards for the current year, maintaining consistency in financial reporting[29]